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Abstract
Background: Many epidemiological studies have shown that the genetic factors of the host play a
role in the variability of clinical response to infection caused by M. leprae. With the purpose of
identifying genes of susceptibility, the present study investigated the possible role of HLA-DRB1
and DQA1/DQB1 alleles in susceptibility to leprosy, and whether they account for the
heterogeneity in immune responses observed following infection in a Southern Brazilian population.
Methods: One hundred and sixty-nine leprosy patients and 217 healthy controls were analyzed
by polymerase chain reaction amplification and reverse hybridization with sequence-specific
oligonucleotide probes and sequence-specific primers(One Lambda®, CA, USA).
Results: There was a positive association of HLA-DRB1*16 (*1601 and *1602) with leprosy per se
(7.3% vs. 3.2%, P = 0.01, OR = 2.52, CI = 1.26–5.01), in accord with previous serological studies,
which showed DR2 as a marker of leprosy. Although, HLA-DQA1*05 frequency (29.8% vs. 20.9%,
P = 0.0424, OR = 1.61, CI = 1.09–2.39) was higher in patients, and HLA-DQA1*02 (3.0% vs. 7.5%,
P = 0.0392, OR = 0.39, CI = 0.16 – 0.95) and HLA-DQA1*04 (4.0% vs. 9.1%, P = 0.0314, OR = 0.42,
CI = 0.19 – 0.93) frequencies lower, P-values were not significant after the Bonferroni's correction.
Furthermore, HLA-DRB1*1601 (9.0% vs. 1.8%; P = 0.0016; OR = 5.81; CI = 2.05–16.46) was
associated with susceptibility to borderline leprosy compared to control group, and while HLA-
DRB1*08 (11.2% vs. 1.2%; P = 0.0037; OR = 12.00; CI = 1.51 – 95.12) was associated with
susceptibility to lepromatous leprosy, when compared to tuberculoid leprosy, DRB1*04 was
associated to protection.
Conclusion: These data confirm the positive association of HLA-DR2 (DRB1*16) with leprosy per
se, and the protector effect of DRB1*04 against lepromatous leprosy in Brazilian patients.
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Background
Leprosy is a chronic infectious disease caused by the intra-
cellular pathogen Mycobacterium leprae [1], whose clinical
manifestations are largely confined to the skin and
peripheral nervous system [2].
Although the global prevalence of leprosy has dropped
dramatically, coinciding with the introduction of multi-
ple-drug therapy, new-case detection rates have remained
stable over the years at approximately 500,000 new cases
per year. The majority of the remaining leprosy cases are
found in India and a few other countries, including Brazil
[3].
Considered a multifactorial disease, the expression of
clinical manifestations of leprosy reflects the relationship
between the host and the parasite. There is a strong corre-
lation between cell-mediated immunity (CMI) against M.
leprae antigens, observed in vitro and in vivo, and the clin-
ical course of the disease. There are five clinical forms of
the disease, ranging between two poles: tuberculoid (TT)
and lepromatous (LL) leprosy. Tuberculoid leprosy is the
result of high cell-mediated immunity, with a largely Th1-
type immune response, and lepromatous leprosy is char-
acterized by low cell-mediated immunity with a humoral
Th2 response [2,4].
Many epidemiological studies, which had the objective of
identifying genes of susceptibility [5], have shown that the
genetic factors of the host play a role in the variability of
clinical response to infection caused by both M. tuberculo-
sis and M. leprae. The Major Histocompatibility Complex
(MHC), located on chromosome 6p21, is the most poly-
morphic genetic system in mammalians, and has been
studied with regard to a wide variety of diseases of distinct
etiology, including infectious diseases. The fundamental
role of the different molecules within the MHC is antigen
processing and presentation to the T-cell receptor (TCR),
which is crucial for the cell interactions in CMI [6].
In humans, while the classic class I loci, HLA-A, -B, and -C,
bind peptides of intra-cellular origin and present them to
CD8+T cells, resulting in the death of cells infected by M.
leprae, the classic class II loci, HLA-DR, -DQ, and -DP, pri-
marily bind peptides of extra-cellular origin and present
them to CD4+T cells, resulting in cytokine production
and T-cell help in antibody production.
While the idea of HLA-related genes being involved in the
control of the clinical progression of leprosy is well docu-
mented, the possible role of the HLA region in susceptibil-
ity to infection per se has also been suggested [7]. Some
results have already been found for class I HLA alleles [8],
however a greater number of studies have reported
increased frequencies of class II alleles in TT and LL
patients in several populations [9-14].
The aims of this study were to determine which HLA class
II polymorphisms affect differential susceptibility to lep-
rosy and whether these account for the heterogeneity in




One hundred and sixty-nine (169) leprosy patients
attended in the 15a Regional de Saúde da Secretaria de
Saúde, Paraná State, Southern Brazil, took part in this
study. All the patients were residents in the cities of Mar-
ingá, Sarandi and Umuarama, and the surrounding
region, in Paraná state. They were classified into four dis-
tinct groups according to clinical and laboratorial (Mit-
suda's test and histology exams) observations made by the
dermatologist responsible for leprosy diagnosis: TT (41
out of the 169 patients, 24.3%), LL (63 patients, 37.3%),
Borderline (49 patients, 29.0%), and Indeterminate (4
patients, 2.4%).
Patient ages at the time of sample collection varied
between 22 and 93 years (mean, 52.8; ± SD, 14.6). How-
ever, leprosy is traditionally a young person's disease, with
a median age at onset of 35 years [15]. Seventy-two
(42.6%) of the patients were female and 97 (57.4%)
male.
The control group was composed of 217 healthy individ-
uals, selected according to age, sex, ethnic group, occupa-
tion and other demographic parameters, with no history
of HLA-associated diseases (hepatitis, auto-immune dis-
eases, HIV and tuberculosis). They were typified by the
Laboratório de Imunogenética of the Universidade Estad-
ual de Maringá. Their ages varied from 20 to 58 years
(mean, 42.0; SD, 7.1), and 106 (48.8%) were female and
111 (51.2%) male.
The population of Paraná is predominantly of European
origin (80.6%), with a small but significant contribution
of African (12.5%) and Amerindian (7.0%) genes [16].
Both the patients and healthy controls were classified as
mixed ethnic groups, according to phenotypic characteris-
tics, because according to Parra et al. (2003) [17], in Bra-
zil, at an individual level, skin color determined by
physical evaluation is a poor predictor of genomic African
ancestry.
The risk of population stratification bias, due to differ-
ences in ethnic background between patients and con-
trols, and variations of allele frequencies, according to
ethnic background, were minimized by matching patients
with control individuals of the same ethnic background,
mean age, gender rates and residence in the same geo-
graphical areas of leprosy prevalence.BMC Infectious Diseases 2009, 9:134 http://www.biomedcentral.com/1471-2334/9/134
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All the participants signed written informed-consent
forms, authorizing the use of their samples in the study,
which was approved by the Ethics Committee for Human
Research at the Universidade Estadual de Maringá.
Determination of HLA class II alleles
Blood samples (10 mL) were collected from the subjects
in tubes containing anticoagulant (EDTA) and centrifuged
at 2,500 rpm for 15 minutes, and the Buffy-coat was con-
served at -20°C until use. The genomic DNA was extracted
by EZ-DNA kits (Biological Industries®, Kibbutz Beit Hae-
mek, Israel) from 150 μL of frozen blood, and then stored
at -20°C.
HLA class II alleles for DRB1* (alleles 01–16), DQA1*
(alleles 01–06) and DQB1* (alleles 02–06) were geno-
typed by combining PCR-SSP (polymerase chain reaction
– sequence-specific primers), using the HLA genotyping
kit [18] with modifications [19] and/or PCR-SSO
(polymerase chain reaction – sequence-specific oligonu-
cleotides) using Luminex (One Lambda®, CA, USA). High
resolution PCR-SSP typing (One Lambda®, CA, USA) was
also used to define the DRB1*04 (0401–0463) and HLA-
DRB1*16 (alleles 1601–1608) alleles, as these loci  are
associated with leprosy.
Statistical analysis
Allele frequency was obtained through direct counting of
the alleles. The allele-frequency distributions were con-
firmed as being in Hardy-Weinberg equilibrium by calcu-
lating the expected frequencies of the genotypes and
comparing them to the observed values using Arlequin
software, version 3.1 [20], available at http://
cmpg.unibe.ch/software/arlequin3.
The analysis of the associations between the HLA varia-
bles and the occurrence of leprosy per se and the LL and TT
subgroups, was performed using the Chi square test, with
the Yates's correction or Fisher's Exact Test when neces-
sary, using the Graph Pad Software program (San Diego,
CA, USA), available at http://www.graphpad.com/quick
calcs/contingency1.cfm. Data were considered statistically
significant when the P value was less than or equal to
0.05. However, to account for multiple comparisons, the
observed P values were corrected (pc) for the number of
alleles when one locus was considered alone.
The odds ratios (OR), with 95% confidence intervals
(95% CI), were calculated using SISA statistics online
http://home.clara.net/sisa/, to evaluate the risk of the
individual developing the disease while having a particu-
lar HLA type.
Results
The possibility of an association between class II HLA alle-
les and leprosy in a population from the south of Brazil
was investigated in this study through the comparison of
the HLA-DRB1, DQA1 and DQB1 allele frequencies of
patients suffering the disease with those of a healthy con-
trol group.
Leprosy per se vs. control group
The HLA-DRB1 and DQA1\DQB1 allele frequencies of
the patients and control group are shown in Tables 1 and
2, respectively. There were differences between leprosy per
se  patients and the control group for HLA-DRB1*16,
which appeared with greater frequency in the patients
(7.3% vs. 3.2%, P = 0.01, OR = 2.52, CI = 1.26–5.01, pc =
0.13). Among the DRB1*16 alleles, DRB1*1602 had the
greatest frequency (3.3% vs. 1.1%, P  = 0.0684). HLA-
DQA1*05 frequency (29.8% vs. 20.9%, P = 0.0424, OR =
1.61, CI = 1.09–2.39, pc = 0.4664) was higher in patients
compared to the control group, while HLA-DQA1*02
(3.0% vs. 7.5%, P = 0.0392, OR = 0.39, CI = 0.16–0.95, pc
= 0.4312), and DQA1*04 (4.0 vs. 9.1, P = 0.0314, OR =
0.42, CI = 0.19–0.93, pc = 0.3454) frequencies were
lower. HLA-DQB1*03 showed a tendency to protection
against leprosy per se (27.3% vs. 33.7%, P = 0.0684).
Leprosy subgroups vs. control group
Table 3 shows the significant differences in HLA frequen-
cies between the control group and the LL, Borderline,
and TT leprosy subtype patients. There were differences in
allelic frequencies between LL patients and the control
group: while DRB1*16 (7.9% vs. 3.2%, P = 0.0405, OR =
2.59, CI = 1.12–5.97) was associated with susceptibility to
Table 1: Frequencies of HLA-DRB1 alleles in leprosy per se 
patients and control group
Alleles Leprosy per se Controls P OR CI 95%
(N = 169) (N = 217)
n% n %
DRB1*01 30 8.8 38 8.8 1
DRB1*03 35 10.3 52 12.0 0.4641
DRB1*04 23 6.8 42 9.7 0.1701
DRB1*07 35 10.3 50 11.5 0.6217
DRB1*08 25 7.3 24 5.5 0.2847
DRB1*09 11 3.2 7 1.6 0.1487
DRB1*10 9 2.66 7 1.6 0.3169
DRB1*11 35 10.3 59 13.6 0.1528
DRB1*12 4 1.1 5 1.2 1
DRB1*13 38 11.2 69 15.9 0.0512
DRB1*14 13 3.8 19 4.4 0.8527
DRB1*15 50 14.7 48 11.1 0.1002
DRB1*16 25 7.3 14 3.2 0.01* 2.52 1.26–5.01
DRB1*1601 13 3.8 8 1.8 0.1126
DRB1*1602 11 3.3 5 1.1 0.0684
DRB1*1605 1 0.2 0 0 0.4378
DRB1*1608 0 0 1 0.2 1
N: number of individuals. n: number of alleles. P : probability. OR: 
odds ratio. CI: confidence interval. *pc: 0.13.BMC Infectious Diseases 2009, 9:134 http://www.biomedcentral.com/1471-2334/9/134
Page 4 of 7
(page number not for citation purposes)
Table 2: Frequencies of HLA-DQA1 e DQB1 alleles in leprosy per se patients and control group
Alleles Leprosy per se Controls P OR CI 95%
(N = 98) (N = 178)
n% n %
DQA1*01 94 47.5 171 45.7 0.9866
DQA1*02 6 3.0 28 7.5 0.0392* 0.39 0.16–0.95
DQA1*03 17 8.6 43 11.5 0.2770
DQA1*04 8 4.0 34 9.1 0.0314** 0.42 0.19–0.93
DQA1*05 59 29.8 78 20.9 0.0424*** 1.61 1.09–2.39
DQA1*06 2 1.0 7 1.9 0.5024
N = 102 N = 184
DQB1*02 39 19.7 59 15.8 0.4110
DQB1*03 54 27.3 126 33.7 0.0684
DQB1*04 11 5.6 19 5.1 0.9063
DQB1*05 40 20.2 66 17.6 0.7032
DQB1*06 53 26.8 104 27.8 0.6258
N: number of individuals. n: number of alleles. P: probability. OR: odds ratio. CI: confidence interval. *pc: 0.4312. **pc: 0.3454. ***pc: 0.4664.
Table 3: Frequencies of HLA class II alleles in leprosy subgroups and control group
Alleles Lepromatous Controls
(N = 63) (N = 217) P OR CI 95%
n% n %
DRB1*04 4 3.2 42 9.7 0.0165 0.31 0.11–0.87
DRB1*16 10 7.9 14 3.2 0.0405 2.59 1.12–5.97
DRB1*1602 6 4.8 5 1.2 0.0197 4.29 1.29–14.30
N = 40 N = 178
DQA1*03 3 3.8 43 11.5 0.0184 0.25 0.07–0.87
DQA1*05 26 32.5 78 20.9 0.0220 2.38 1.17–4.86
N = 40 N = 184
DQB1*02 22 27.5 59 15.8 0.0103 2.59 1.29–5.19
Borderline Controls
(N = 44) (N = 217)
DRB1*09 6 6.8 7 1.6 0.0112 4.74 1.51–14.87
DRB1*16 8 9.0 14 3.2 0.0175 3.22 1.26–8.23
DRB1*1601 8 9.0 8 1.8 0.0016* 5.81 2.05–16.46
N = 30 N = 178
DQA1*04 1 1.7 34 9.1 0.0337 0.15 0.02–1.11
Tuberculoid Controls
(N = 45) (N = 217)
DRB1*1602 4 4.4 5 1.1 0.0498 4.14 1.07–16.06
N = 24 N = 178
DQA1*02 0 0 28 7.5 0.0298 0.23 0.03–1.8
DQA1*05 18 37.5 78 20.9 0.0046 3.85 1.46–10.15
N: number of individuals. n: number of alleles. P: probability. OR: odds ratio. CI: confidence interval. *pc: 0.0208.BMC Infectious Diseases 2009, 9:134 http://www.biomedcentral.com/1471-2334/9/134
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the LL form, DRB1*04 (3.2% vs. 9.7%, P = 0.0165, OR =
0.31, CI = 0.11–0.87) was associated with protection
against it. On further, high-resolution, analysis of the
DRB1*04 and DRB1*16 alleles, only DRB1*1602 fre-
quency was higher in LL patients than in the control group
(4.8% vs. 1.2%, P = 0.0197, OR = 4.29, CI = 1.29–14.30).
HLA-DQA1*03 frequency was lower (3.8% vs. 11.5%, P =
0.0184, OR = 0.25, CI = 0.07–0.87), while DQA1*05
(32.5% vs. 20.9%, P = 0.0220, OR = 2.38, CI = 1.17–4.86)
and DQB1*02 (27.5% vs. 15.8%, P = 0.0103, OR = 2.59,
CI = 1.29–5.1) frequencies were higher in LL patients
compared to the control group.
HLA-DRB1*09 (6.8 vs. 1.6%, P = 0.0112, OR = 4.74, CI =
1.51–14.87) and DRB1*16 (9.0% vs. 3.2%, P = 0.0175,
OR = 3.22, CI = 1.26–8.23) frequencies were higher in
Borderline patients than in the control group. On further,
high-resolution, analysis, only DRB1*1601 frequency was
higher in these patients (9.0% vs. 1.8%, P = 0.0016, OR =
5.81, CI = 2.05–16.46, pc = 0.0208). HLA-DQA1*04 fre-
quency was lower in Borderline patients than in the con-
trol group (1.7% vs. 9.1%, P = 0.0337, OR = 0.15, CI =
0.02–1.11).
In patients with TT leprosy, although DRB1*16 frequency
was not different to that of the control group, the
DRB1*1602 allele frequency was found to be higher
(4.4% vs. 1.1%, P = 0.0498, OR = 4.14, CI = 1.07–16.06).
Furthermore, HLA- DQA1*05 frequency was higher
(37.5% vs. 20.9%, P = 0.0046, OR = 3.85, CI = 1.46–
10.15), while DQA1*02 frequency was lower (0% vs.
7.5%, P = 0.0298, OR = 0.23, CI = 0.03–1.80) in these
patients.
Lepromatous leprosy vs. Tuberculoid leprosy
When comparing the opposite poles of the disease (LL vs.
TT) (Table 4), a difference was observed for HLA-
DRB1*04 (3.2% vs. 12.8%; P = 0.0090; OR = 0.20; CI =
0.06–0.67, pc = 0.117), which was associated with protec-
tion against the LL form. HLA-DRB1*08 was associated
with a predisposition to LL leprosy (11.2% vs. 1.2%; P =
0.0037; OR = 12.00; CI = 1.51 – 95.12, pc = 0.0481), and
HLA-DRB1*14 showed a tendency towards association
with these patients (1.5% vs. 6.9%; P = 0.0595).
No statistically significant difference in the allele fre-
quency distributions was observed between LL and TT
forms for HLA-DQA and DQB alleles (data not shown).
Discussion
This case-control study investigated the genetic variation
present in HLA-DRB1, DQA1 and DQB1 genes, and its
relation to leprosy in Southern Brazil.
In infection caused by M. leprae, HLA alleles influence not
only susceptibility or resistance to the disease, but also the
course of the disease. The main role of HLA molecules is
to present peptides derived from M. leprae to the T cells of
the host. Susceptibility to an infectious disease may be
due to imperfections in some stages of this system. An
individual that has a particular combination of HLA alle-
les that are not linked to the peptide in an appropriate
way, or for whom the HLA-peptide linkage does not
develop a proper lymphocyte response, will be less able to
resist the invasion of the infectious agent than an individ-
ual that does not have such deficiencies [21]. In patients
whose HLA systems offer protection against the disease,
these genes probably select and stimulate T cells that mul-
tiply and eliminate the agent with inflammatory cytokine
production, or else destroy the infected cells [22].
Several studies identify a consistent form for the participa-
tion of HLA alleles and haplotypes, especially class II
genes, as an important genetic factor associated to leprosy.
The clinical manifestation of the disease depends on the
type of immune response shown by the host, and
exchanges between Th1 and Th2 response types may be
partially controlled by a mechanism of antigen presenta-
tion involving HLA molecules [23]. In the TT form of the
disease, the production of proinflammatory cytokines by
Th1 cells may help in the clearance of the bacillus. How-
ever, in the LL form, the immunosuppressor cytokines
produced by the Th2 response may make this response
difficult.
In the present study, HLA-DRB1*16, a subtype of DR2,
participates as a susceptibility marker for leprosy per se,
confirming previous serological results that showed an
Table 4: HLA-DRB1 allele frequencies in Lepromatous (LL) and 
Tuberculoid (TT) leprosy patients
LL TT
Alleles (N = 63) (N = 43) P OR CI 95%
n%n%
DRB1*01 12 9.5 11 12.8 0.5745
DRB1*03 13 10.3 13 15.1 0.3693
DRB1*04 4 3.2 11 12.8 0.0090* 0.20 0.06–0.67
DRB1*07 14 11.2 9 10.4 0.8741
DRB1*08 14 11.2 1 1.2 0.0037** 12.00 1.51–95.12
DRB1*09 4 3.2 2 2.3 1.0000
DRB1*10 4 3.2 1 1.2 0.6462
DRB1*11 11 8.7 11 12.8 0.4422
DRB1*12 2 1.5 1 1.2 1.0000
DRB1*13 14 11.2 7 8.1 0.6131
DRB1*14 2 1.5 6 6.9 0.0595
DRB1*15 21 16.6 9 10.5 0.2410
DRB1*16 10 7.9 5 5.8 0.5850
DRB1*1601 3 2.4 0 0 0.2698
DRB1*1602 6 4.8 5 5.8 0.7544
N: number of individuals. n: number of alleles. P: probability. OR: odds 
ratio. CI: confidence interval. * pc: 0.117. **pc: 0.0481.BMC Infectious Diseases 2009, 9:134 http://www.biomedcentral.com/1471-2334/9/134
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association between HLA-DR2 and leprosy per se in
patients from an equivalent geographical area (South Bra-
zil) [11]. The association of HLA-DR2 (now DRB1*15
and DRB1*16) with susceptibility to leprosy per se has
been highlighted in other studies [24,25] and in LL and TT
patients, compared to healthy controls, in many popula-
tions around the world (Surinam, India, Venezuela,
Egypt, Chine, Japan, Korea, Mexico, Turkey, Brazil)
[reviewed in [12,26]]. Associations with the class II region
are thought to occur due to the class II restriction of the
presentation of mycobacterial epitopes to T-helper cells.
Rani et al. (1992), in Korean, showed positive associa-
tions of HLA-DR2 and DQ1 with LL leprosy, and DR9 and
DQ7 with Borderline leprosy; and negative associations
between DR4 and DQ3 and LL leprosy [7]. The present
study is in accord with these results: HLA-DRB1*DR9 was
associated with susceptibility to Borderline leprosy and
HLA-DRB1*04 was associated with protection against LL
leprosy, as a lower frequency was observed in these
patients compared to in the TT group, and DQB1*03
showed a tendency towards protection. Strong linkage
disequilibria, in some populations, are known to exist
within the MHC (gene order: HLA-DQB1, DQA1, DRB1)
[27-29]. The weak positive association of DQB1*03 with
protection against leprosy (Table 2) may be due to the
strong linkage disequilibrium between DRB1*04 and this
DQ allele.
Similar results for DRB1*04 were reported by Joko et al.
(2000) for leprosy per se in a Japanese population [30]
and, more recently, by both Vanderborght et al. (2007) in
both Brazilian and Vietnamese populations [14] and
Motta et al. (2007) in an Argentinean population [31].
In addition, according to the data of the present study,
HLA-DRB1*08 frequency was higher in lepromatous
patients than tuberculoid patients, indicating a role in sus-
ceptibility to the most severe form of leprosy.
Rani et al. (1993) found a significantly higher frequency
of DQB1*0601 in leprosy patients than in healthy con-
trols, while DQA1*0103 was most frequent in LL patients
and DQA1*0102 was selectively higher in borderline lep-
romatous patients [32]. On the other hand, DRB1*0701,
DQB1*0201 and DQA1*0201 frequencies were all lower
in multibacillary leprosy patients compared to TT patients
and controls, and DQB1*0503 was selectively lower in TT
patients. In the present study, HLA-DQA1*05 frequency
was significantly higher in leprosy patients, while
DQA1*02 and *04 frequencies were lower.
An unrelated genome-wide scan in 71 multi-case families
from Brazil found chromosome region 6p21 (lod = 3.23)
to be weakly linked to leprosy [33]. More detailed analysis
indicated that more than one locus in each of these dense
immune-response gene regions might affect susceptibility
to leprosy, including genes that contribute to leprosy per
se and to lepromatous, as opposed to tuberculoid, disease
subtypes [13]. Early candidate-gene analysis, usually
involving the HLA region on chromosome 6p21, has pro-
vided the first experimental evidence for the complex
nature of the genetic variations involved in host genetic
susceptibility to leprosy. It is therefore necessary that
research be continued via a study with a larger number of
patients in each group in order to verify the genes that are
possibly related to protection against and susceptibility to
leprosy, and to disease progression, in this Brazilian pop-
ulation.
Conclusion
Although there was great genotypic variety in the Brazilian
population, the results of the present study confirm the
significant participation of HLA-DR2 (DRB1*16) and
DQA1 in susceptibility to leprosy per se, and the participa-
tion of HLA-DRB1*04 in protection and of DRB1*08 in
susceptibility to the severe form of the disease (leproma-
tous leprosy). Therefore, HLA-DRB1*1601 was associated
with susceptibility to Borderline leprosy. Taken together,
these HLA analyses suggest the possibility of there being
more than one locus of leprosy susceptibility in the MHC.
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